High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme
Abstract There are currently few approved effective treatments for SARS-CoV-2, the virus responsible for the COVID-19 pandemic. Nanobodies are 12–15 kDa single-domain antibody fragments that can be delivered by inhalation and are amenable to relatively inexpensive large scale production compared to...
Enregistré dans:
Auteurs principaux: | , , , , |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2020
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/781613999e5f4819ab8747154b1624dd |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|